Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.

Antimicrobial Agents and Chemotherapy
Joseph F StandingMaria N Tsolia

Abstract

Detailed oseltamivir pharmacokinetics have yet to be reported in neonates and infants; this group is at high risk of serious influenza-associated complications. Extrapolation of doses from older patients is complicated by rapid organ and drug-metabolizing enzyme maturation. A pharmacokinetic study has been conducted during an influenza A(H1N1) outbreak in a neonatal intensive care unit. Each included patient provided 4 samples for oseltamivir and 4 samples for its active metabolite oseltamivir carboxylate. A population pharmacokinetic model was developed with NONMEM. Allometric weight scaling and maturation functions were added a priori to scale for size and age based on literature values. Nine neonates and infants were recruited. A physiologically parameterized pharmacokinetic model predicted typical day 1 area under the curve (AUC(0-12)) values of 1,966 and 2,484 μg · h/liter for neonates and infants of ≤ 37 weeks of postmenstrual age (PMA) and >37 weeks of PMA treated with 1 mg/kg of body weight and 2 mg/kg, respectively. The corresponding steady-state AUC(0-12) values were 3,670 and 4,559 μg · h/liter. Premature neonates treated with 1 mg/kg and term babies treated with 2 mg/kg should have average oseltamivir carboxylate co...Continue Reading

References

Sep 24, 1999·The Pediatric Infectious Disease Journal·F M MunozJ A Englund
Feb 27, 2001·The Pediatric Infectious Disease Journal·R J WhitleyP Ward
Jan 5, 2002·Journal of Pharmacokinetics and Pharmacodynamics·S L Beal
Jan 9, 2003·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
Jul 30, 2003·Archives of Internal Medicine·Laurent KaiserFrederick Hayden
Aug 12, 2003·European Journal of Clinical Pharmacology·Charles OoPenelope Ward
Sep 19, 2003·The New England Journal of Medicine·Gregory L KearnsRalph E Kauffman
Nov 5, 2003·Critical Reviews in Toxicology·Paul S PriceDouglas R Tedder
Sep 16, 2004·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
Sep 24, 2004·Journal of Pharmacokinetics and Pharmacodynamics·Jakob Ribbing, E Niclas Jonsson
Nov 2, 2005·Expert Opinion on Pharmacotherapy·John Oxford
Nov 25, 2005·British Journal of Clinical Pharmacology·L Aarons
Nov 24, 2006·Journal of Perinatology : Official Journal of the California Perinatal Association·D J WilkinsonC C Andersen
Apr 26, 2007·Journal of Clinical Pharmacology·Jerome J SchentagCraig R Rayner
Jan 15, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Allison McGeerUNKNOWN Toronto Invasive Bacterial Diseases Network
Mar 14, 2008·Clinical Pharmacokinetics·Michel TodGérard Pons
Jun 6, 2008·Journal of Clinical Pharmacology·Craig R RaynerE Niclas Jonsson
Oct 11, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Malin M RhodinNick H G Holford
Jun 25, 2010·Pediatric Pulmonology·Ahmet SertHüseyin Bilgin
Jul 3, 2010·The Journal of Infectious Diseases·Edward P AcostaUNKNOWN National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group
Sep 8, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Santtu HeinonenTerho Heikkinen
Dec 18, 2010·Paediatric Drugs·Susan M Abdel-RahmanGregory L Kearns
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Feb 11, 2011·Current Infectious Disease Reports·Guillermo Domínguez-CheritJose Angel Cordova-Villalobos
Oct 1, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·UNKNOWN Centers for Disease Control and Prevention

❮ Previous
Next ❯

Citations

Dec 12, 2012·The Journal of Infectious Diseases·David W KimberlinUNKNOWN National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group
Jul 20, 2014·Advances in Pediatrics·Daniel GonzalezMichael Cohen-Wolkowiez
Nov 5, 2015·Expert Opinion on Drug Metabolism & Toxicology·Elena Yu EnioutinaCatherine M Sherwin
Jun 5, 2015·British Journal of Clinical Pharmacology·Venkateswaran C PillaiRaman Venkataramanan
May 29, 2014·Clinical Pharmacology and Therapeutics·M A KamalC R Rayner
Jan 27, 2016·British Journal of Clinical Pharmacology·Kalayanee ChairatJoel Tarning
Mar 27, 2018·Clinical Pharmacology and Therapeutics·Joseph F StandingUNKNOWN FLACSAM-PK Study Group
Sep 25, 2018·Journal of Clinical Pharmacology·Stephen J Balevic, Michael Cohen-Wolkowiez
Feb 3, 2019·British Journal of Clinical Pharmacology·Kevin M WattUNKNOWN Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
Dec 20, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy M UyekiAndrew T Pavia
Oct 22, 2016·British Journal of Clinical Pharmacology·Eva GermovsekJoseph F Standing
Oct 12, 2021·Journal of Chemotherapy·Marco Antonio MotisiElena Chiappini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.